Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alastair Clemow joins Medgenics' board

This article was originally published in Clinica

Executive Summary

Israeli firm Medgenics has appointed Alastair Clemow to its board of directors. He will fill the seat left vacant by the death of Lord Leonard Steinberg last November (www.clinica.co.uk, 10 November 2009). Dr Clemow worked for Johnson & Johnson from 1981 until 2000 in various positions, including vice-president of worldwide business development for its Ethicon Endo-Surgery unit, and director of research and development in J&J's orthopaedic division. He has also been president and CEO of spinal specialists Gelifex and Nexgen Spine, and currently holds the same positions at Israeli tissue repair company Regentis Biomaterials. Misgav-based Medgenics' lead product is the Epodure Biopump, which is designed to deliver therapeutic proteins. It is currently in a Phase I/II trial where it is being used to manufacture erythropoietin in anaemia patients.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT095458

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel